Related Experiment Video

Updated: Apr 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Enzalutamide in metastatic prostate cancer before chemotherapy

Tomasz M Beer, Bertrand Tombal

    The New England Journal of Medicine
    |October 30, 2014
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Serum and Plasma Copy Number Detection Using Real-time PCR
    09:21

    Serum and Plasma Copy Number Detection Using Real-time PCR

    Published on: December 15, 2017

    10.7K
    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    1.1K

    Related Experiment Videos

    Last Updated: Apr 21, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    13.4K
    Serum and Plasma Copy Number Detection Using Real-time PCR
    09:21

    Serum and Plasma Copy Number Detection Using Real-time PCR

    Published on: December 15, 2017

    10.7K
    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    1.1K

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.1K
    1.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    2.6K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    2.6K

    Articles linked to this work by shared authors, journal, and citation graph.

    Real-world treatment patterns and clinical outcomes in patients with non-muscle invasive bladder cancer: a nationwide evaluation.

    World journal of urology·2026

    EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

    European urology·2026

    Active surveillance for intermediate-risk prostate cancer: a systematic review and pooled analysis.

    BJU international·2026

    Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

    European urology·2026

    Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

    European journal of cancer (Oxford, England : 1990)·2026

    Beyond GnRH analogues: The renaissance of estrogens in prostate cancer management.

    The French journal of urology·2026

    Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis.

    The New England journal of medicine·2026

    Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

    The New England journal of medicine·2026

    Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.

    The New England journal of medicine·2026

    Eplontersen for Transthyretin Amyloid Cardiomyopathy.

    The New England journal of medicine·2026

    Myeloproliferative Neoplasms.

    The New England journal of medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us